Cargando…

Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number

BACKGROUND: Postoperative radiation (PORT) is an option for non-small cell lung cancer (NSCLC) patients with resectable stage IIIA pathological N2 status (pN2). For patients with PORT, this study aims to investigate the impact of the exact number of positive lymph nodes (LNs) on overall survival (OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siwei, Ma, Zhifei, Yang, Xiangbao, Wang, Yajing, Xu, Youtao, Xia, Wenjia, Chen, Rui, Qiu, Mantang, Jiang, Feng, Yin, Rong, Xu, Lin, Xu, Keping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747172/
https://www.ncbi.nlm.nih.gov/pubmed/29284511
http://dx.doi.org/10.1186/s13014-017-0946-1
_version_ 1783289236760297472
author Wang, Siwei
Ma, Zhifei
Yang, Xiangbao
Wang, Yajing
Xu, Youtao
Xia, Wenjia
Chen, Rui
Qiu, Mantang
Jiang, Feng
Yin, Rong
Xu, Lin
Xu, Keping
author_facet Wang, Siwei
Ma, Zhifei
Yang, Xiangbao
Wang, Yajing
Xu, Youtao
Xia, Wenjia
Chen, Rui
Qiu, Mantang
Jiang, Feng
Yin, Rong
Xu, Lin
Xu, Keping
author_sort Wang, Siwei
collection PubMed
description BACKGROUND: Postoperative radiation (PORT) is an option for non-small cell lung cancer (NSCLC) patients with resectable stage IIIA pathological N2 status (pN2). For patients with PORT, this study aims to investigate the impact of the exact number of positive lymph nodes (LNs) on overall survival (OS) and lung cancer-specific survival (LCSS). METHODS: Within the Surveillance, Epidemiology, and End Results database, we identified 3373 patients with stage IIIA pathological N2 status (pN2) NSCLC who underwent a lobectomy or pneumonectomy from 2004 to 2013. OS and LCSS were compared among patients coded as receiving PORT or observation. The proportional hazards model was applied for investigation. RESULTS: OS and LCSS favored PORT for patients with stage IIIA (pN2) NSCLC. Multivariable analyses showed that PORT and the exact number of positive LNs (n ≤ 3) were independently associated with better OS and LCSS. Both better OS and LCSS emerged for positive LNs (n > 3) after the use of PORT in survival analyses, whereas the benefits of OS and LCSS were not observed anymore for positive LNs (n ≤ 3) group. More importantly, multivariable analyses showed that the use of PORT is an independent risk factor of survival for positive LNs (n > 3) but not for positive LNs (n ≤ 3). CONCLUSIONS: In Stage IIIA (pN2) NSCLC, the use of PORT demonstrated better survival results than no PORT for patients with positive LNs (n > 3), but not for patients with positive LNs (n ≤ 3). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-017-0946-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5747172
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57471722018-01-03 Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number Wang, Siwei Ma, Zhifei Yang, Xiangbao Wang, Yajing Xu, Youtao Xia, Wenjia Chen, Rui Qiu, Mantang Jiang, Feng Yin, Rong Xu, Lin Xu, Keping Radiat Oncol Research BACKGROUND: Postoperative radiation (PORT) is an option for non-small cell lung cancer (NSCLC) patients with resectable stage IIIA pathological N2 status (pN2). For patients with PORT, this study aims to investigate the impact of the exact number of positive lymph nodes (LNs) on overall survival (OS) and lung cancer-specific survival (LCSS). METHODS: Within the Surveillance, Epidemiology, and End Results database, we identified 3373 patients with stage IIIA pathological N2 status (pN2) NSCLC who underwent a lobectomy or pneumonectomy from 2004 to 2013. OS and LCSS were compared among patients coded as receiving PORT or observation. The proportional hazards model was applied for investigation. RESULTS: OS and LCSS favored PORT for patients with stage IIIA (pN2) NSCLC. Multivariable analyses showed that PORT and the exact number of positive LNs (n ≤ 3) were independently associated with better OS and LCSS. Both better OS and LCSS emerged for positive LNs (n > 3) after the use of PORT in survival analyses, whereas the benefits of OS and LCSS were not observed anymore for positive LNs (n ≤ 3) group. More importantly, multivariable analyses showed that the use of PORT is an independent risk factor of survival for positive LNs (n > 3) but not for positive LNs (n ≤ 3). CONCLUSIONS: In Stage IIIA (pN2) NSCLC, the use of PORT demonstrated better survival results than no PORT for patients with positive LNs (n > 3), but not for patients with positive LNs (n ≤ 3). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-017-0946-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-29 /pmc/articles/PMC5747172/ /pubmed/29284511 http://dx.doi.org/10.1186/s13014-017-0946-1 Text en © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Siwei
Ma, Zhifei
Yang, Xiangbao
Wang, Yajing
Xu, Youtao
Xia, Wenjia
Chen, Rui
Qiu, Mantang
Jiang, Feng
Yin, Rong
Xu, Lin
Xu, Keping
Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title_full Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title_fullStr Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title_full_unstemmed Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title_short Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
title_sort choice of postoperative radiation for stage iiia pathologic n2 non-small cell lung cancer: impact of metastatic lymph node number
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747172/
https://www.ncbi.nlm.nih.gov/pubmed/29284511
http://dx.doi.org/10.1186/s13014-017-0946-1
work_keys_str_mv AT wangsiwei choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT mazhifei choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT yangxiangbao choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT wangyajing choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT xuyoutao choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT xiawenjia choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT chenrui choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT qiumantang choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT jiangfeng choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT yinrong choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT xulin choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber
AT xukeping choiceofpostoperativeradiationforstageiiiapathologicn2nonsmallcelllungcancerimpactofmetastaticlymphnodenumber